Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Siamab Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Siamab Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Siamab Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Siamab Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Siamab Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 9
Siamab Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Siamab Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Siamab Therapeutics (Sialix) Secures USD3.21 Million in Venture Funding 11
Siamab Therapeutics Raises USD2 Million in Venture Financing 12
Siamab Therapeutics Raises USD0.5 Million in Venture Financing 13
Sialix Raises US$2.5 Million In Venture Financing 14
Sialix Raises US$4 Million In Series B Financing 15
Siamab Therapeutics Raises USD0.4 Million in Venture Financing 16
Partnerships 17
Siamab Therapeutics and Boehringer Ingelheim Enter into Discovery Agreement 17
Licensing Agreements 18
Sialix Enters Into Licensing Agreement With Momenta Pharma For Monoclonal Antibody Therapeutic Program 18
Siamab Therapeutics Inc – Key Competitors 19
Siamab Therapeutics Inc – Key Employees 20
Siamab Therapeutics Inc – Locations And Subsidiaries 21
Head Office 21
Recent Developments 22
Product News 22
04/04/2018: Siamab Therapeutics to Present New Data on its ST1 Antibody Therapeutic Program Targeting Tumor-Associated STn and STn+ Myeloid Derived Suppressor Cells at the AACR Annual Meeting 2018 22
Clinical Trials 23
May 01, 2018: Siamab Therapeutics Announces Publication of New Data on its ST1 Lead Program in the Journal Oncotarget 23
Jan 03, 2018: Siamab Therapeutics to Present New Data on its ST1 Antibody Therapeutic Program Targeting Tumor-Associated STn and MDSCs at Biotech Showcase 2018 24
Oct 30, 2017: Siamab Therapeutics Presents New Preclinical Safety Data for ST1 Antibody Therapeutics Program at the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 25
Oct 03, 2017: Siamab Therapeutics Presents New Data at AACR’s Ovarian Cancer Conference Demonstrating its Anti-STn Antibody Therapeutics Inhibit Tumor Growth in Ovarian Cancer Models 26
Apr 04, 2017: Siamab Therapeutics Presents New Preclinical Data for Its Novel Anti-STn Antibodies and Anti-STn Bispecific Antibodies at the AACR Annual Meeting 2017 27
Apr 04, 2017: Siamab Therapeutics Presents New Preclinical Data On ST-1 at the AACR Annual Meeting 2017 28
Mar 21, 2017: Siamab Therapeutics to Present New Preclinical Data for Its Novel Antibodies and Antibody Drug Candidates at the American Association for Cancer Research Annual Meeting 2017 29
Mar 08, 2017: Siamab Therapeutics Announces Publication of New Preclinical Data in the Journal mAbs Describing its Novel Monoclonal Antibody Approach to Targeting the Tumor-Associated Carbohydrate Antigen STn 30
Appendix 31
Methodology 31
About GlobalData 31
Contact Us 31
Disclaimer 31
Siamab Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Siamab Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Siamab Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Siamab Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Siamab Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Siamab Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 9
Siamab Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Siamab Therapeutics (Sialix) Secures USD3.21 Million in Venture Funding 11
Siamab Therapeutics Raises USD2 Million in Venture Financing 12
Siamab Therapeutics Raises USD0.5 Million in Venture Financing 13
Sialix Raises US$2.5 Million In Venture Financing 14
Sialix Raises US$4 Million In Series B Financing 15
Siamab Therapeutics Raises USD0.4 Million in Venture Financing 16
Siamab Therapeutics and Boehringer Ingelheim Enter into Discovery Agreement 17
Sialix Enters Into Licensing Agreement With Momenta Pharma For Monoclonal Antibody Therapeutic Program 18
Siamab Therapeutics Inc, Key Competitors 19
Siamab Therapeutics Inc, Key Employees 20
List of Figures
Siamab Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Siamab Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Siamab Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Siamab Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Siamab Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Siamab Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Siamab Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Siamab Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Siamab Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 9
【免責事項】
http://www.globalresearch.jp/disclaimer